Introduction
The salutary effects of hydroxyurea (HU) in sickle cell anemia (SS) include decreased frequency of painful crises, decreased incidence of acute chest syndrome, decreased blood transfusion, and decreased mortality and morbidity (1) (2) (3) (4) (5) . Markers of the response to HU include increased Hb F level, macrocytosis, improved RBC survival and deformability, and decreased WBC count (!- 7) . In this study we report markers of early response to HU by using generalized linear mixed models (GLM) to determine the relationship between HU usage and the longitudinal trajectories of RBC indices and the corresponding longitudinal trajectories of reticulocytes indices. 
Methods

Results
The mean weeks (wks) of follow-up from study enrollment date was 86.6 wks (standard deviation (sd)=38.84 wks; max=172 wks, median=84 wks, min=10 wks). The mean age of this patient cohort at the start of follow-up was 29.0 years (SD =4 .77 years; max=37 years, median=30 years, min=19 years). There were 13 males (61.9%) and 8 females (38.1%).
Goodness-of-fit criteria for the GLM indicated that the RBC indices modeled more precisely than those of reticulocytes. However, both the RBC indices and reticulocytes provided useful information regarding the relationship between their longitudinal trajectories and HU usage ( Table 1) .
There was a significant relationship between HU usage and the following longitudinal trajectories: mean cell hemoglobin (CH) (p<.0001), reticulocyte mean cell hemoglobin (CHr) (p<.0001); Cell hemoglobin concentration mean (CHCM) (p=.0394); Reticulocyte mean cell volume (MCVr) (p=.0019); hemoglobin distribution width (HDW) (p=.0003) and red blood cell volume distribution width (RDW) (p=.0008). HU usage produced higher value trajectories than those generated by placebo usage for the following: CH, CHr; and MCVr (Fig. 1) . These changes were first detected 10 weeks after starting HU and before the increase in Hb F levels.
Discussion
Although HU has been proven to have salutary effects in patients with SS (1-3) its utilization continues to suffer from two major drawbacks. These include its underutilization (16) and the fact that at least 25% of patients who take it are nonresponders to its use (1, 2) . These two drawbacks seem to re-enforce each other. Thus some patients may be falsely labeled as non-responders if no effect on frequency of painful crises and/or no increase in the level of Hb F is seen within 2-3 months after starting HU at a dose of 10-15 mg/k/day. The reason why some patients do not respond to HU is unknown. One possibility is that it fails to recruit dormant bone marrow fetal stem cells that are capable to produce fetal Hb. Moreover, it usually takes at least six months of therapy with HU before an increase in Hb F is seen (7) . Thus an early sign of a response-in-progress to HU therapy is important information for the provider who is monitoring the the clinical and hematological data of patients after the initiation of therapy with HU.
In this study we report markers of early response to HU by using generalized linear mixed models (GLM) to determine the relationship between HU usage and the longitudinal trajectories of RBC parameters and the corresponding longitudinal trajectories of reticulocytes parameters. Specifically HU therapy showed significant changes in the Hb content (CHr) and cell volume of reticulocyte (MCVr) compared to placebo within 10 weeks after starting HU indicating an early sign of response to therapy.
Thus the sequence of signs of response to HU include increase in reticulocyte indices (CHr and MCVr) within 10 weeks after therapy followed by increase in RBC indices and a later increase (up to six months) in Hb F level.
Conclusion
Together the data suggest that subtle and early markers of response to HU reside in the hemogram. This is a fast, simple and inexpensive methodology provided the lab in question has the capability to determine the indices of both reticulocytes and RBC.
